MX2014014543A - Medicina que comprende la combinacion de un anestesico general e hidrogeno. - Google Patents
Medicina que comprende la combinacion de un anestesico general e hidrogeno.Info
- Publication number
- MX2014014543A MX2014014543A MX2014014543A MX2014014543A MX2014014543A MX 2014014543 A MX2014014543 A MX 2014014543A MX 2014014543 A MX2014014543 A MX 2014014543A MX 2014014543 A MX2014014543 A MX 2014014543A MX 2014014543 A MX2014014543 A MX 2014014543A
- Authority
- MX
- Mexico
- Prior art keywords
- anesthetic
- hydrogen
- medicine
- general
- hydrogen gas
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012125535 | 2012-05-31 | ||
| PCT/JP2013/065094 WO2013180240A1 (ja) | 2012-05-31 | 2013-05-30 | 全身麻酔薬と、水素とを組み合わせてなる、医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014014543A true MX2014014543A (es) | 2015-06-05 |
Family
ID=49673427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014014543A MX2014014543A (es) | 2012-05-31 | 2013-05-30 | Medicina que comprende la combinacion de un anestesico general e hidrogeno. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150079197A1 (enExample) |
| EP (1) | EP2857026A4 (enExample) |
| JP (1) | JP6168420B2 (enExample) |
| KR (1) | KR20150018832A (enExample) |
| CN (1) | CN104394873A (enExample) |
| AU (1) | AU2013268366A1 (enExample) |
| BR (1) | BR112014029260A2 (enExample) |
| CA (1) | CA2874579A1 (enExample) |
| HK (1) | HK1205450A1 (enExample) |
| IL (1) | IL235718A0 (enExample) |
| IN (1) | IN2014MN02090A (enExample) |
| MX (1) | MX2014014543A (enExample) |
| NZ (1) | NZ701553A (enExample) |
| RU (1) | RU2014152690A (enExample) |
| SG (1) | SG11201407489TA (enExample) |
| WO (1) | WO2013180240A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6253029B2 (ja) * | 2015-01-21 | 2017-12-27 | 大陽日酸株式会社 | 麻酔器用取付キット |
| US20180338995A1 (en) * | 2017-05-23 | 2018-11-29 | Perricone Hydrogen Water Company, Llc | Systems and methods for treatments using hydrogen and/or noble gases |
| US11129848B2 (en) * | 2017-08-08 | 2021-09-28 | Perricone Hydrogen Water Company, Llc | Medication enhancement using hydrogen |
| US20210222174A1 (en) * | 2018-06-29 | 2021-07-22 | John Mansell | Compositions and methods for the treatment of anesthesia-induced neurotoxicity |
| US11123365B2 (en) | 2019-11-18 | 2021-09-21 | Perricone Hydrogen Water Company, Llc | Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof |
| JP7019910B2 (ja) * | 2020-07-21 | 2022-02-16 | ＭｉＺ株式会社 | 薬の副作用、薬の副作用に関連する症状、および／または、治療に伴う副作用を予防および／または改善するための組成物 |
| CN117861037A (zh) * | 2022-10-11 | 2024-04-12 | 上海氢医医疗科技有限公司 | 氢气吸入治疗自闭症 |
| CN119303200A (zh) * | 2024-12-17 | 2025-01-14 | 山东百多安医疗器械股份有限公司 | 一种可以释放氢气减少神经损伤的麻醉机 |
-
2013
- 2013-05-30 MX MX2014014543A patent/MX2014014543A/es unknown
- 2013-05-30 WO PCT/JP2013/065094 patent/WO2013180240A1/ja not_active Ceased
- 2013-05-30 CN CN201380028933.5A patent/CN104394873A/zh active Pending
- 2013-05-30 AU AU2013268366A patent/AU2013268366A1/en not_active Abandoned
- 2013-05-30 NZ NZ701553A patent/NZ701553A/en not_active IP Right Cessation
- 2013-05-30 US US14/397,229 patent/US20150079197A1/en not_active Abandoned
- 2013-05-30 JP JP2014518736A patent/JP6168420B2/ja not_active Expired - Fee Related
- 2013-05-30 BR BR112014029260A patent/BR112014029260A2/pt not_active Application Discontinuation
- 2013-05-30 KR KR20147035945A patent/KR20150018832A/ko not_active Withdrawn
- 2013-05-30 CA CA2874579A patent/CA2874579A1/en not_active Abandoned
- 2013-05-30 RU RU2014152690A patent/RU2014152690A/ru unknown
- 2013-05-30 IN IN2090MUN2014 patent/IN2014MN02090A/en unknown
- 2013-05-30 HK HK15103729.5A patent/HK1205450A1/en unknown
- 2013-05-30 EP EP13796554.7A patent/EP2857026A4/en not_active Withdrawn
- 2013-05-30 SG SG11201407489TA patent/SG11201407489TA/en unknown
-
2014
- 2014-11-16 IL IL235718A patent/IL235718A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150018832A (ko) | 2015-02-24 |
| CA2874579A1 (en) | 2013-12-05 |
| WO2013180240A1 (ja) | 2013-12-05 |
| EP2857026A4 (en) | 2015-11-04 |
| US20150079197A1 (en) | 2015-03-19 |
| BR112014029260A2 (pt) | 2017-06-27 |
| JP6168420B2 (ja) | 2017-07-26 |
| SG11201407489TA (en) | 2014-12-30 |
| IN2014MN02090A (enExample) | 2015-09-04 |
| NZ701553A (en) | 2016-06-24 |
| RU2014152690A (ru) | 2016-07-20 |
| IL235718A0 (en) | 2015-01-29 |
| EP2857026A1 (en) | 2015-04-08 |
| AU2013268366A1 (en) | 2015-03-19 |
| JPWO2013180240A1 (ja) | 2016-01-21 |
| HK1205450A1 (en) | 2015-12-18 |
| CN104394873A (zh) | 2015-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014014543A (es) | Medicina que comprende la combinacion de un anestesico general e hidrogeno. | |
| Rawat et al. | Ketamine activates adult-born immature granule neurons to rapidly alleviate depression-like behaviors in mice | |
| Frau et al. | Prenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone | |
| Bertolino et al. | Beneficial effects of co‐ultramicronized palmitoylethanolamide/luteolin in a mouse model of autism and in a case report of autism | |
| Dong et al. | Melatonin attenuated early brain injury induced by subarachnoid hemorrhage via regulating NLRP 3 inflammasome and apoptosis signaling | |
| González et al. | Modafinil improves methamphetamine-induced object recognition deficits and restores prefrontal cortex ERK signaling in mice | |
| Almeida-Suhett et al. | Reduced GABAergic inhibition in the basolateral amygdala and the development of anxiety-like behaviors after mild traumatic brain injury | |
| Karen et al. | Effect of propofol in the immature rat brain on short-and long-term neurodevelopmental outcome | |
| Chen et al. | Prolonged mechanical ventilation–induced neuroinflammation affects postoperative memory dysfunction in surgical mice | |
| Siopi et al. | Etazolate, an α-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice | |
| Samantaray et al. | Chronic intermittent ethanol induced axon and myelin degeneration is attenuated by calpain inhibition | |
| Zhang et al. | Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization | |
| Takahashi et al. | Activation of cholinergic system partially rescues olfactory dysfunction-induced learning and memory deficit in mice | |
| Logue et al. | Sex-specific effects of social isolation stress and ketamine on hippocampal plasticity | |
| Lei et al. | Leptin enhances social motivation and reverses chronic unpredictable stress-induced social anhedonia during adolescence | |
| Abumaria et al. | Magnesium supplement enhances spatial-context pattern separation and prevents fear overgeneralization | |
| Flores et al. | Neonatal olfactory bulbectomy enhances locomotor activity, exploratory behavior and binding of NMDA receptors in pre-pubertal rats | |
| Haelewyn et al. | Neuroprotection by nitrous oxide: facts and evidence | |
| Nimitvilai et al. | Sex‐dependent differences in ethanol inhibition of mouse lateral orbitofrontal cortex neurons | |
| Harding et al. | Prenatal exposure to valproic acid and treatment with intranasal oxytocin have sex-specific effects on behavior in Long Evans rats | |
| Tourrel et al. | The antiapoptotic effect of remifentanil on the immature mouse brain: an ex vivo study | |
| Li et al. | SEP‐363856 exerts neuroprotection through the PI3K/AKT/GSK‐3β signaling pathway in a dual‐hit neurodevelopmental model of schizophrenia‐like mice | |
| Iida et al. | Analgesic effect of linalool odor on oral ulcerative mucositis-induced pain in rats | |
| Cheng et al. | mPFC DCC coupling with CaMKII+ neuronal excitation participates in behavioral despair in male mice | |
| Zhao et al. | Morphine pretreatment protects against cerebral ischemic injury via a cPKCγ-mediated anti-apoptosis pathway |